Aclarion Inc. (ACON)
| Bid | 5.08 |
| Market Cap | 5.45M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -804.49 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 5.33 |
| Volume | 530,173 |
| Avg. Volume (20D) | 390,302 |
| Open | 4.87 |
| Previous Close | 4.51 |
| Day's Range | 4.65 - 5.75 |
| 52-Week Range | 3.86 - 539.35 |
| Beta | undefined |
About ACON
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclari...
Analyst Forecast
According to 2 analyst ratings, the average rating for ACON stock is "Hold." The 12-month stock price forecast is $481, which is an increase of 8873.88% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · prismmediawire.com
Aclarion Announces CLARITY Trial for Nociscan Now Fully FundedBroomfield, CO, February 4, 2025 – PRISM MediaWire – Aclarion, Inc.
3 weeks ago · prismmediawire.com
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine ConferenceBROOMFIELD, Colo., January 31, 2025 – PRISM MediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprieta...
